Skip to main content

Market Overview

Unity Biotech Shares Open For Trade

Share:
Unity Biotech Shares Open For Trade

Unity Biotechnology, Inc. (NASDAQ: UBX) went public on Thursday under the stock symbol UBX.

What Happened

The company issued 5 million shares at $17 each, raising $85 million in its initial public offering. It had previously set $16 to $18 as a price range for its shares. The stock opened for trading at $19 or approximately 12 percent above the IPO price.

Why It's Important

The company is developing medicines that potentially halt, slow or reverse age-associated diseases and it has yet to show that its drugs are successful. It is planning to initiate a Phase 1 clinical trial in osteoarthritis and recently raised $55 million for this purpose. Unity is also planning clinical trials for UBX 1967, a potential treatment for ophthalmologic diseases.

What's Next

Unity has granted underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the initial public offering price less the underwriting discounts and commissions. The offering is expected to close on May 7.

The stock pulled back after a strong start and closed Thursday's trading session down 2.06 percent at $16.65. 

Related Links:

The IPO Outlook For The Week Of April 30: Aslan Pharma, Inspire Medical, Unity Biotech And More

3 Tech IPOs We Want In 2018

 

Related Articles (UBX)

View Comments and Join the Discussion!

Posted-In: Biotech News Offerings General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com